JP2012519691A5 - - Google Patents

Download PDF

Info

Publication number
JP2012519691A5
JP2012519691A5 JP2011553059A JP2011553059A JP2012519691A5 JP 2012519691 A5 JP2012519691 A5 JP 2012519691A5 JP 2011553059 A JP2011553059 A JP 2011553059A JP 2011553059 A JP2011553059 A JP 2011553059A JP 2012519691 A5 JP2012519691 A5 JP 2012519691A5
Authority
JP
Japan
Prior art keywords
cycloalkyl
alkyl
interferon
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011553059A
Other languages
English (en)
Japanese (ja)
Other versions
JP5690286B2 (ja
JP2012519691A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/025991 external-priority patent/WO2010101967A2/en
Publication of JP2012519691A publication Critical patent/JP2012519691A/ja
Publication of JP2012519691A5 publication Critical patent/JP2012519691A5/ja
Application granted granted Critical
Publication of JP5690286B2 publication Critical patent/JP5690286B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011553059A 2009-03-04 2010-03-03 ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤 Expired - Fee Related JP5690286B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15721109P 2009-03-04 2009-03-04
US61/157,211 2009-03-04
PCT/US2010/025991 WO2010101967A2 (en) 2009-03-04 2010-03-03 Phosphothiophene and phosphothiazole hcv polymerase inhibitors

Publications (3)

Publication Number Publication Date
JP2012519691A JP2012519691A (ja) 2012-08-30
JP2012519691A5 true JP2012519691A5 (US07794700-20100914-C00152.png) 2013-04-11
JP5690286B2 JP5690286B2 (ja) 2015-03-25

Family

ID=42123028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011553059A Expired - Fee Related JP5690286B2 (ja) 2009-03-04 2010-03-03 ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤

Country Status (5)

Country Link
US (1) US8193372B2 (US07794700-20100914-C00152.png)
EP (1) EP2403860B1 (US07794700-20100914-C00152.png)
JP (1) JP5690286B2 (US07794700-20100914-C00152.png)
TW (1) TW201036988A (US07794700-20100914-C00152.png)
WO (1) WO2010101967A2 (US07794700-20100914-C00152.png)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013009551A (es) * 2011-02-24 2013-09-06 Jiangsu Hanson Pharmaceutical Co Ltd Compuestos que contienen fosforo como inhibidores de proteina cinasa.
MY190867A (en) 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US10766917B2 (en) 2015-05-27 2020-09-08 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EA037868B1 (ru) 2016-09-07 2021-05-28 Атеа Фармасьютикалс, Инк. 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
AR110768A1 (es) 2017-01-31 2019-05-02 Gilead Sciences Inc Formas cristalinas de tenofovir alafenamida
JP7066728B2 (ja) 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
CN108586527B (zh) * 2018-06-01 2020-03-31 郑州大学 芳基膦酸酯类化合物及其制备方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN111196823A (zh) * 2020-03-10 2020-05-26 郑州大学 一种3-膦酰化苯并噻吩类化合物及制备方法

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
DE2064307A1 (de) * 1970-12-29 1972-07-06 Bayer Ag Thiazolo-(thiono)-phosphor-(phosphon)säureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Insektizide
FR2135690A5 (en) * 1971-03-17 1972-12-22 Roussel Uclaf O,o-dialkyl o-(5-alkoxycarbonyl-2-methyl-4-thiazolyl) - phosphates and thiophosphates - as acaricides and insecticides
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
FR2300768A1 (fr) * 1975-02-14 1976-09-10 Roussel Uclaf Nouveaux composes thiopeniques phosphoryles, procede de preparation et application comme pesticides
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
AU660925B2 (en) 1990-04-06 1995-07-13 Genelabs Technologies, Inc. Hepatitis C virus epitopes
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU3262593A (en) * 1992-01-11 1993-08-03 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP3217191B2 (ja) * 1992-07-16 2001-10-09 ビーエーエスエフ アクチェンゲゼルシャフト ヘテロ芳香族化合物およびこれを含有する植物保護剤
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
CN1078478C (zh) 1993-02-24 2002-01-30 王瑞駪 活性抗病毒聚合物的组成及应用方法
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
CA2167537A1 (en) 1993-07-19 1995-02-02 Tsuneo Ozeki Hepatitis c virus proliferation inhibitor
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO1995008550A1 (en) 1993-09-24 1995-03-30 Abbott Laboratories Endothelin antagonists
DE4415539C2 (de) 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
DE4432623A1 (de) 1994-09-14 1996-03-21 Huels Chemische Werke Ag Verfahren zur Bleichung von wäßrigen Tensidlösungen
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5696112A (en) * 1995-01-17 1997-12-09 American Cyanamid Company Fused heterocyclic azepines as vasopressin antagonists
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
JP3786447B2 (ja) 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
ATE268591T1 (de) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
AU6299496A (en) 1995-06-29 1997-01-30 Novo Nordisk A/S Novel substituted azabicyclic compounds
US6022868A (en) 1995-06-29 2000-02-08 Novo Nordisk Als Substituted azacyclic or azabicyclic compounds
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
WO1997032018A2 (en) 1996-02-29 1997-09-04 Immusol, Inc. Hepatitis c virus ribozymes
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
AU722289B2 (en) 1996-10-01 2000-07-27 Aptalis Pharmatech, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
IL129407A0 (en) 1996-10-18 2000-02-17 Vertex Pharma Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
IL129394A (en) * 1996-10-24 2002-05-23 Novartis Ag Amino-alkaline phosphonic acids are converted
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries Ltd Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US5994563A (en) * 1997-04-01 1999-11-30 Ortho Pharmaceutical Corporation Arylmethylphosphonic acid derivatives useful in treating bone wasting diseases
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
TW593225B (en) 1997-06-30 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane NMDA receptor antagonists
NZ503263A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
BR9908270A (pt) 1998-02-25 2004-06-29 Univ Emory 2-fluoro-nucleosìdeos, composições farmacêuticas e seus usos
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
HUP0204092A3 (en) * 1999-12-22 2005-02-28 Metabasis Therapeutics Inc San Novel bisamidate phosphononate prodrugs
KR20030005197A (ko) 2000-02-18 2003-01-17 샤이어 바이오켐 인코포레이티드 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법
PL359359A1 (en) 2000-04-05 2004-08-23 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
DE60136620D1 (de) 2000-04-13 2009-01-02 Pharmasset Inc 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
CZ20023473A3 (cs) 2000-04-19 2003-01-15 Schering Corporation Makrocyklická sloučenina a farmaceutický prostředek
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
RU2355700C9 (ru) 2000-07-21 2010-03-20 Шеринг Корпорейшн Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с
EP1301527A2 (en) 2000-07-21 2003-04-16 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
BR0112666A (pt) 2000-07-21 2003-06-10 Schering Corp Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
CN1646141B (zh) 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
WO2002060926A2 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
ES2324594T3 (es) 2000-12-12 2009-08-11 Schering Corporation Diaril peptidicos utilizados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
AU2002232660A1 (en) 2000-12-15 2002-06-24 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
JP2004527504A (ja) 2001-03-01 2004-09-09 フアーマセツト・リミテツド ２’，３’−ジデオキシ−２’，３’−ジデヒドロヌクレオシドの合成法
WO2003070750A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc Rna interference mediated inhibition of hepatitis c virus
US20040209831A1 (en) 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
ATE438637T1 (de) * 2001-06-11 2009-08-15 Virochem Pharma Inc Thiophenderivate als antivirale mittel gegen flavivirus-infektion
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
FR2831884B1 (fr) * 2001-11-02 2003-12-26 Pf Medicament Nouveaux derives amides heteroaromatiques de 3 beta-amino azabicyclooctane, leur procede de preparation et leurs applications en therapeutique
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
EP1506000B9 (en) 2002-05-20 2011-08-31 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
DE60336550D1 (de) 2002-05-20 2011-05-12 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
WO2004002999A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
PL374792A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
DE602004029866D1 (de) 2003-03-05 2010-12-16 Boehringer Ingelheim Pharma Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
ES2381548T3 (es) 2003-04-11 2012-05-29 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente de la proteasa VHC NS3-NS4A
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
EP1644395B1 (en) 2003-06-19 2006-11-22 F. Hoffmann-La Roche Ag Processes for preparing 4'azido nucleoside derivatives
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
US20050043266A1 (en) 2003-07-25 2005-02-24 Sumedha Jayasena Short interfering RNA as an antiviral agent for hepatitis C
RU2006115558A (ru) 2003-10-10 2007-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы
EP2407470A3 (en) 2003-10-14 2015-06-10 F. Hoffmann-La Roche Ltd. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
DE10359791A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
KR100773524B1 (ko) * 2003-12-24 2007-11-07 삼성에스디아이 주식회사 이핵 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
WO2005073214A2 (en) * 2004-01-23 2005-08-11 Janssen Pharmaceutica, N.V. Novel inhibitors of chymase
JP2007525510A (ja) 2004-02-27 2007-09-06 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしての化合物
EP1730142B1 (en) 2004-02-27 2011-06-29 Schering Corporation Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
TW200612914A (en) * 2004-03-05 2006-05-01 Hoffmann La Roche Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
AU2005236002A1 (en) * 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
EP1763531A4 (en) 2004-06-28 2009-07-01 Boehringer Ingelheim Int ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES
EP1765819B1 (en) 2004-06-30 2014-03-12 Vertex Pharmaceuticals Inc. Azaindoles useful as inhibitors of protein kinases
CA2577526A1 (en) 2004-08-23 2006-03-02 Joseph Armstrong Martin Antiviral 4'-azido-nucleosides
EP1797111B1 (en) 2004-08-27 2011-06-22 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
RS50981B (sr) * 2004-09-17 2010-10-31 Idenix Pharmaceuticals Inc. Fosfoindoli kao hiv inhibitori
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
JP4880473B2 (ja) 2004-10-08 2012-02-22 壽製薬株式会社 ホスホン酸誘導体及び血中の高リン酸が関与する疾患の治療剤
US7879797B2 (en) 2005-05-02 2011-02-01 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20070021351A1 (en) 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
JP2009500334A (ja) * 2005-06-29 2009-01-08 シェーリング コーポレイション Ｃｘｃ−ケモカインレセプターリガンドとしてのジ置換オキサジアゾール
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
BRPI0613962A2 (pt) 2005-07-25 2009-03-24 Intermune Inc inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007014925A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis c virus
US20070105781A1 (en) 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR058586A1 (es) 2005-12-22 2008-02-13 Smithkline Beecham Corp Compuesto de 2-carboxitiofeno, formulacion farmaceutica que lo comprende, su uso para la preparacion de un medicamento y combinacion de dicho compuesto con otro agente terapeuticamente activo
EP2043658B1 (en) * 2006-07-07 2012-04-25 Gilead Sciences, Inc. Antiviral phosphinate compounds
WO2008017688A1 (en) 2006-08-11 2008-02-14 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti-viral agents
WO2008043791A2 (en) 2006-10-13 2008-04-17 Smithkline Beecham Corporation Thiophene derivatives for treating hepatitis c
WO2008059042A1 (en) * 2006-11-17 2008-05-22 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti viral agents

Similar Documents

Publication Publication Date Title
JP2012519691A5 (US07794700-20100914-C00152.png)
RU2718917C2 (ru) Комбинированное лечение агонистом толл-подобного рецептора (tlr7) и ингибитором сборки капсида вируса гепатита в
JP2013523765A5 (US07794700-20100914-C00152.png)
RU2010112408A (ru) Фосфадиазиновые ингибиторы iv полимеразы hcv
JP2013538235A5 (US07794700-20100914-C00152.png)
JP2013538230A5 (US07794700-20100914-C00152.png)
RU2016122908A (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
JP2013514359A5 (US07794700-20100914-C00152.png)
JP2011518835A5 (US07794700-20100914-C00152.png)
JP2010514768A5 (US07794700-20100914-C00152.png)
AU2018204107A1 (en) Solid forms of a toll-like receptor modulator
JP2011521903A5 (US07794700-20100914-C00152.png)
JP2019500387A5 (US07794700-20100914-C00152.png)
JP2010515760A5 (US07794700-20100914-C00152.png)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
CA2632626A1 (en) Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
CA2490200A1 (en) 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
JP2018500372A5 (US07794700-20100914-C00152.png)
JP2012517444A5 (US07794700-20100914-C00152.png)
HRP20140370T1 (hr) 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman
JP2010505902A5 (US07794700-20100914-C00152.png)
JP2008514732A5 (US07794700-20100914-C00152.png)
JP2011520906A5 (US07794700-20100914-C00152.png)
JP2011520772A5 (US07794700-20100914-C00152.png)
JP2011511841A5 (US07794700-20100914-C00152.png)